ALX Oncology Holdings announced that Jason Lettmann, a member of the Board of Directors, will succeed Jaume Pons as CEO, effective September 6. Pons will transition to the role of Chief Scientific Officer and remain President and both executives will remain members of the Board of Directors. Jason Lettmann has been involved with ALX Oncology for nearly a decade since its founding, having co-led the Company’s first institutional financing and serving as a member of the Company’s Board of Directors since 2015. Jason brings to the CEO post a broad suite of expertise relevant to ALX Oncology at its current stage of development including serving as CEO of Promedior, a biotechnology company developing targeted medicines to treat fibrosis.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ALXO:
- ALX Oncology Realigns Executive Leadership Team
- ALX Oncology risk/reward ‘compelling’ into data, say Piper Sandler
- ALX Oncology files to sell 18.45M shares of common stock for holders
- ALX Oncology Announces September Investor Conference Participation
- ALX Oncology price target lowered to $8 from $48 at Piper Sandler